Key result
Integrated cardio-oncology care optimizes cardiovascular surveillance and preserves cancer therapy access in multiple myeloma.
Why the study?
Cardiovascular complications in multiple myeloma patients and the need for integrated systems-based cardiovascular management were not comprehensively reviewed.
An integrated cardio-oncology approach is essential to manage cardiovascular risk, cardiotoxicity, and cardiac amyloidosis in patients undergoing therapy for multiple myeloma.
Answers are grounded in this paper and cite their sources.
May inform institutional cardio-oncology pathways in multiple myeloma; leaves open prospective validation of outcomes.
PURPOSE OF REVIEW: This review examines cardiovascular complications of multiple myeloma and anti-myeloma therapy, emphasising integrated systems-based cardiovascular management and the institutional model developed at the University College London Hospital Cardio-Oncology (CO) Centre of Excellence. RECENT FINDINGS: Cardiovascular vulnerability in multiple myeloma reflects baseline risk, disease-related factors, including cardiac amyloidosis, and treatment-related cardiotoxicity. A longitudinal approach should begin before therapy with multidimensional risk stratification incorporating patient, disease, and treatment factors, with intermediate- and high-risk patients referred for CO review. During treatment, active surveillance using clinical assessment, cardiac biomarkers and imaging, with vigilance for cardiac amyloidosis, enables rapid CO referral and timely intervention. Survivorship care should include annual cardiovascular review, risk-factor optimisation, and monitoring for late toxicity. Existing evidence and real-world experience support integrated CO services combining rapid-access clinics, high-volume cardiac imaging, timely decision-making, inpatient consultation, multidisciplinary collaboration, and survivorship surveillance while preserving cardiovascular health and access to effective anti-myeloma therapy.
No takes yet. Share an insight, caveat, or question.
Akrawi et al. (2026) conducted a review in Multiple myeloma. Integrated systems-based cardiovascular management was evaluated. An integrated systems-based approach to cardiovascular management in multiple myeloma enables risk stratification, active surveillance, and survivorship care while preserving access to therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: